spacer
home > pmps > winter 2017 > formulating a plan
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Formulating a Plan

High doses are often necessary to deliver enough of an orally administered drug to the lungs or nasal passages through the bloodstream. As many medicines are now highly potent, delivery by mouth has the potential to cause severe side effects. Combined with this, when products are taken in this way they are easily metabolised, which means that they are not always adequately administered to the nose or lungs, thus limiting the success of the treatment.

In contrast, inhalation formulations enable pharmaceuticals to be delivered directly to the nasal passages or lungs in smaller doses, reducing the risks of both side effects and drug-to-drug interaction. Their growth in popularity can further be attributed to their ability to give the most direct access to a drug target. For example, many inhaled products are steroid drug classes. They can have a harmful impact on growth and hormone balance if taken in large amounts by children and is, therefore, beneficial to deliver a smaller dose to the site of action.

These local therapies offer fast absorption, rapid response and enable a drug to be administered straight to the conducting zone of the lungs. As a result, they work particularly well for conditions such as asthma. Inhalation also represents a very attractive way to deliver drugs to the brain. In the treatment of migraines, for instance, nasal spray drug delivery into the nose can bring fast and effective relief.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Poonam Aliyah Sheth is a Research Scientist specialising in inhalation product development at Recipharm and she holds a PhD in Pharmaceutical Science from the University of Arizona, US. With particular expertise in MDI formulations, dry powder inhalers and nebulised formulations, she has been integral to the development and manufacture of many original and generic products for inhalation drug delivery for global clients, ranging from emerging to large pharmaceutical organisations.

Ramil Menzeleev, PhD, is Director of Recipharm’s Analytical Sciences department. He oversees analytical method development, providing scientific review for client projects while also participating in the design and development of electronic data recording software platforms. A specialist in analytical chemistry, his expertise covers fast, highly sensitive, accurate and high-throughput quantitation method development. He also manages the selection and implementation of IT solutions, including software for business process management, as well as review and approval software for design, validation, implementation and use in Good Manufacturing Practice environments.
spacer
Poonam Aliyah Sheth
spacer
spacer
spacer
Ramil Menzeleev
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Illingworth Research Group hires in Australia

Illingworth Research, a UK headquartered CRO with medical photography and mobile research nursing services has appointed Joanne Lemura as the Research Nursing Team Manager, based in Melbourne Australia to help further expand our mobile nursing services throughout Australasia.
More info >>

White Papers

Convergence in the Pharmaceutical Market

PCI Pharma Services

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

 
Industry Events

DIA 2017 Annual Meeting

18-22 June 2017, Chicago, IL

Themed “Driving Insights to Action,” DIA 2017 will host 8,000+ professionals in the pharmaceutical, biotechnology, and medical device communities from more than 50 countries. DIA 2017 boasts more than 450 exhibiting companies, 10+ tracks, and 160+ sessions focused on regulatory science, translational medicine, patient engagement, and value and access. Follow DIA 2017 updates on Twitter using #DIA2017.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement